Orthocell Reports Revenue Growth for September Quarter
The company recorded A$3.6 million in revenue as sales for its nerve repair product continue to rise.
Updated on Oct. 22, 2026 in Healthcare
Live Poll
Do you trust that rapid medical product adoption in new markets prioritizes patient well-being over profits?
Orthocell generated A$3.6 million in total revenue during the September 2026 quarter. This performance was driven by significant gains in the adoption of its Remplir nerve repair product across several international markets.
Why it matters
The steady growth in unit sales and expanding hospital network indicate increasing market penetration for the companys nerve repair technology. This momentum supports the ongoing commercialization strategy without requiring additional capital.
Global Remplir revenue increased 20% compared to the previous quarter, with the product now accounting for over 40% of total revenue. Additionally, the company ended September with A$39 million in available funds.
The players
Orthocell
Orthocell is a regenerative medicine company that develops products for nerve repair and soft tissue regeneration.
The details
The firm expanded its US distributor network to cover 70% of the population and secured its first national contract. International reach also grew, marked by the first commercial sales of Remplir in Thailand.
Timeline
Orthocell generated A$3.6 million in revenue during the September 2026 quarter.
The company targets regulatory clearance in the UK and European markets by the end of 2026.
Market Landscape
Orthocell is aggressively scaling its presence within the Remplir nerve repair market to capture a larger share of global surgical procedures. This expansion positions the firm to compete more effectively against traditional treatment modalities as it moves toward potential UK and European entry.
The increased adoption of Remplir by 79 hospitals and 93 surgeons suggests that medical facilities are integrating the technology into their standard nerve repair procedures. Patients may see broader access to these treatments as the company expands its network of hospitals and clinical partners.
The takeaway
Orthocell remains well-funded to continue its international commercialization without needing further capital raises. The company is now focused on securing European and UK regulatory approvals to further scale its operations.
What happens next
Orthocell expects to receive regulatory clearance for its products in the United Kingdom and European markets by the end of 2026.
Further reading
For more news on medical sector developments, visit our Healthcare section.
Live Poll
Do you trust that rapid medical product adoption in new markets prioritizes patient well-being over profits?
